Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non small cell lung cancer (NSCLC) patients harboring BRAF mutation: Clinical characteristics and management in real world setting. Cohort BRAF EXPLORE GFPC 02-14

Date

08 Oct 2016

Session

Poster Display

Presenters

Jean Bernard Auliac

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

J.B. Auliac1, S. Bayle2, A. Vergnenegre3, G. Fraboulet4, H. Lecaer5, L. Falchero6, P. Dô7, H. Doubre8, P.A. Hauss9, A. Vinas10, S. Larive11, A.M. Chiappa12, B. Marin13, C. Chouaid10

Author affiliations

  • 1 Service De Pneumologie Et Oncologie Thoracique, CH François Quesnay, 78200 - Mantes La Jolie/FR
  • 2 Pneumologie, Centre Hospitalier Universitaire de Saint-Etienne, St. Etienne/FR
  • 3 Service De L'uotc, CHU Limoges - Hopital Dupuytren, 87042 - Limoges/FR
  • 4 Oncologie, Hopital René Dubos, Pontoise/FR
  • 5 Oncologie, CH de la Dracénie-Draguignan, Draguignan/FR
  • 6 Pneumologie, Hôpital Nord Ouest, Villefranche sur Saone/FR
  • 7 Oncologie, Centre Francois Baclesse, Caen/FR
  • 8 Oncologie, Hopital Foch Service d'Oncologie, Suresnes/FR
  • 9 Pneumologie, ch elbeuf, elbeuf/FR
  • 10 Pneumologie, CH Intercommunal de Créteil, Créteil/FR
  • 11 Pneumologie, Centre Hospitalier, Macon/FR
  • 12 Pneumologie, CH de Cornouaille - Hopital Laennec, Quimper/FR
  • 13 Centre D’epidémiologie, De Biostatistique Et De Methodologie De La Recherche (cebimer), CHU Limoges - Hopital du Cluzeau, Limoges/FR
More

Resources

Background

BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutation is a rare oncogenic driver in NSCLC (2%) and few data are published on the management of these patients (pts) outside patients included in clinical trial. Objective: to investigate clinical characteristics and management of these patients in real world setting.

Methods

Inclusion of pts with a diagnosis of NSCLC harboring BRAF mutations between January 2012 and December 2014, collection of demographic and clinical characteristics, risk factors, Progression Free Survival (PFS), Overall Survival (OS), mode of progression and therapeutic management; sub group analysis according to the BRAF mutation (V600E versus others).

Results

59 patients recruited in 24 centers: 34 (57,6%) men; age: 64,5 ± 14,5 years; PS 0/1 at diagnosis: 82%; current/former smokers: 23 (40,3%)/18 (32,6%); adenocarcinoma: 93%; Stage at diagnosis 4/3/2-1: 77%/16%/7%: BRAF V600E: 81%; co-mutations EGFR n = 2, ALK n = 2. Outcomes of stage IV (n = 44): first line treatment: chemotherapy: 61,9%, chemotherapy + radiotherapy : 9,5%, radiotherapy alone: 2.4%, Best supportive care (BSC): 11.9 %, anti BRAF: 14.2 %; response rate and PFS to first line treatment: 51.7% and 8.7 months (CI 6.4; 15.2), second line treatment (n = 21) : chemotherapy: 66.7%, anti BRAF 23.8%, BSC 9.5%; response rate and PFS to second line treatment: 35.3% and 4,8 months (CI 2,7;10,3); 2 years-OS: 58.5% (CI 45.8; 74.8). 17 pts received BRAF inhibitor. Outcome of stage IV BRAF harboring V600 E (n = 32) didn't showed any significant difference.

Conclusions

In this real world analysis, the majority of NSCLC patients with BRAF mutation were men, smokers and appears to have a better survival to NSCLC pts without oncogenic driver.

Clinical trial identification

EXPLORE GFPC 02-14 comité d'Ethique du CHU de Saint-Etienne Commission recherche de Terre d'éthique: IRBN 102016/CHUSTE

Legal entity responsible for the study

N/A

Funding

Clinical trial information: Supported by an academic grant from Lilly, Astra Zeneca, boehringer ingelheim

Disclosure

J.B. Auliac: In the last five years, honoraria for attending scientific meetings, speaking, organizing research or consulting, from Boehringer Ingelheim, Hoffman-Roche, Lilly and Pfizer. A. Vergnenegre: In the last five years, Honoraria for attending scientific meetings, speaking, organizing research or consulting, from Boehringer Ingelheim, Hoffman- Roche, Lilly. C. Chouaid: Honoraria for attending scientific meetings, speaking, organizing research or consulting, from Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman-la Roche, Sanofi Aventis, Lilly, Novartis and Amgen. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings